Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dyne Therapeutics, Inc. (DYN : NSDQ)

• Company Description    Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 258

• Price / Volume Information    Yesterday's Closing Price: $16.07 Daily Weekly Monthly 20 Day Moving Average: 3,191,956 shares Shares Outstanding: 186.75 (millions) Market Capitalization: $3,001.01 (millions) Beta: 1.12 52 Week High: $27.31 52 Week Low: $14.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.99% -1.64% 12 Week -35.98% -39.62% Year To Date -17.84% -27.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1560 TRAPELO ROAD - WALTHAM,MA 02451 USA ph: 781-786-8230 fax: 781-786-8866 ir@dyne-tx.com http://www.dyne-tx.com

• General Corporate Information    Officers John G. Cox - President; Chief Executive Officer and Director Jason Rhodes - Director and Chairman of the Board Erick Lucera - Chief Financial Officer and Treasurer Ed Hurwitz - Director Carlo Incerti - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 26818M108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 186.75 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $3,001.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.85 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.27 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -11.34% vs. Previous Quarter: -47.95% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -64.30 03/31/26 - -58.28 ROA 09/30/26 - - 06/30/26 - -50.33 03/31/26 - -46.77 Current Ratio 09/30/26 - - 06/30/26 - 12.02 03/31/26 - 19.92 Quick Ratio 09/30/26 - - 06/30/26 - 12.02 03/31/26 - 19.92 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 3.76 03/31/26 - 5.24 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.28 03/31/26 - 0.17 Debt-to-Capital 09/30/26 - - 06/30/26 - 22.11 03/31/26 - 14.73

Powered by Zacks Investment Research ©